TY - JOUR T1 - Ramipril reduced mortality and cardiovascular morbidity in high risk adults JF - Evidence Based Medicine JO - Evid Based Med SP - 47 LP - 47 DO - 10.1136/ebm.5.2.47 VL - 5 IS - 2 A2 - , Y1 - 2000/03/01 UR - http://ebm.bmj.com/content/5/2/47.abstract N2 - (2000) N Engl J Med 342, 145. The Heart Outcomes Prevention Evaluation Study Investigators.. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients.. Jan 20;. :. –53.OpenUrlCrossRefPubMedWeb of Science
 
 QUESTION: In adults who are at high risk for cardiovascular (CV) events, does ramipril, an angiotensin converting enzyme (ACE) inhibitor, reduce CV events? (Vitamin E results will be reported separately.) Randomised {allocation concealed*}†, blinded (patients, clinicians, and outcome assessors),* controlled 2×2 factorial design trial with planned interim analyses (Heart Outcomes Prevention Evaluation [HOPE] study). 161 centres in North America, 76 in 14 western European countries, and 30 in Argentina and Brazil. 9541 adults (mean age 66 y, 73% men) who were aged ≥55 years and had a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes and ≥1 other CV risk factor. Exclusion criteria were heart failure, ejection fraction <0.4, use of an ACE inhibitor, uncontrolled hypertension, … ER -